VaramirStart free · no cardSign in
ALLO as of Oct 31 · 09:23 ET
ALLONasdaqBiological Products, (No Diagnostic Substances)

Allogene Therapeutics, Inc. · Brief

Next report

5 days

Nov 5 · after closeest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
0 of 8≥ implied
avg implied
±24.2%
avg realized
±6.5%
Nov 7 '24±25.2%▼−3.45%×0.14
Mar 13 '25±23.8%▲+2.65%×0.11
May 13 '25±21.3%▼−15.68%×0.74
Aug 13 '25±39.7%▲+2.88%×0.07
Q3 FY25±23.5%▲+12.38%×0.53
Q1 FY26±33.1%▼−2.83%×0.09
May 13 '26±14.0%▼−8.15%×0.58
Q2 FY26±13.3%▼−4.35%×0.33
quarterimplied−40%0+40%realized×
Q2 FY26±13.3%▼−4.35%×0.33
May '26±14.0%▼−8.15%×0.58
Q1 FY26±33.1%▼−2.83%×0.09
Q3 FY25±23.5%▲+12.38%×0.53
Aug '25±39.7%▲+2.88%×0.07
May '25±21.3%▼−15.68%×0.74
2 older reports
Mar '25±23.8%▲+2.65%×0.11
Nov '24±25.2%▼−3.45%×0.14
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 5 report · est.

Bull2 of 3

13disclosed supplier and customer ties in SEC filingsSEC filings
209managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 3

4tracked funds holding ALLON-PORT · Aug 31 '26
0.24%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

ALLO report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 22impliedImplied move: ±28.3% into Nov 5 earnings (Oct 22 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.